DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: TWYNSTA

Summary for Tradename: TWYNSTA

Patents:1
Applicants:1
NDAs:1
Suppliers: see list1
Formulation / Manufacturing:see details
drug
patent expirations by year for
 TWYNSTA

Clinical Trials for: TWYNSTA

A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
Status: Recruiting Condition: Hypertension

Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
Status: Active, not recruiting Condition: Hypertension

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
Status: Completed Condition: Hypertension

ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT)
Status: Recruiting Condition: Hypertension and Atrial Fibrillation

Telmisartan, Amlodipine and Flow Mediated Dilation
Status: Active, not recruiting Condition: Hypertension

Telmisartan 80mg Non-responder Trial
Status: Completed Condition: Hypertension

Telmisartan and Amlodipine Versus Monocomponent Tablets
Status: Completed Condition: Hypertension

TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch
Status: Completed Condition: Hypertension

Open Label Study Telmisartan and Amlodipine in Hypertension
Status: Completed Condition: Hypertension

Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes
Status: Completed Condition: Hypertension; Obesity; Diabetes

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
TWYNSTA
amlodipine besylate; telmisartan
TABLET;ORAL022401Oct 16, 2009RXNo5,591,762<disabled>YY<disabled>
Boehringer Ingelheim
TWYNSTA
amlodipine besylate; telmisartan
TABLET;ORAL022401Oct 16, 2009RXYes5,591,762<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc